The nation of Zimbabwe has declined a significant US health deal worth 367 million US dollars (272 million pounds) over five years due to the United States' demand for confidential data.
This rejection came to light following a official document from December was disclosed, indicating that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government representative later stated that the United States was demanding access to genetic material for scientific study and commercial purposes while was not willing to share the benefits from future vaccines.
"We are forced to start the challenging and unfortunate process of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more negotiations to secure a agreement suitable to both sides so the nation's vital HIV programme can be sustained.
Wider Implications
Zimbabwe's decision follows a similar situation in Kenya, where a high court halted a related deal with the US after legal challenges were raised about the security of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
Based on reports, Sixteen African countries have to date signed these new health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy via US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to share its biological resources and data indefinitely, without any corresponding promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the basic resources for medical research without any certainty that the final treatments would be accessible to our citizens should a future pandemic emerge."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were undermining systems already established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its data, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," he added.
"We are open to further discussions with our American counterparts on how future collaboration might be designed in a manner that honours the independence and interests of each country."
Health Experts Response
Medical experts stated it recognised the official position, but urged that negotiations should continue since much of the country's HIV programmes were funded by external financing.
"Where technical issues exist, such as those involving data governance or implementation frameworks, these can often be resolved via detailed discussion and negotiated safeguards," it said.
The halted deal emphasises the continuing tensions between receiving vital foreign assistance and safeguarding a country's data in an ever more data-driven world.